Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.

No link between vitamin D and metabolic syndrome among female SLE patients

06 Nov 2019

Higher serum 25‐hydroxyvitamin D (25(OH)D) concentrations confer no protective benefit in terms of metabolic syndrome in nondiabetic women with systemic lupus erythematosus (SLE), a study suggests.

The study included 160 nondiabetic SLE women (mean age, 43.3 years), most of whom had mild disease activity (median SLEDAI‐2K score, 2; median disease duration, 11 years). The proportion of patients with an SDI ≥1 was 33.1 percent. Eighty-eight percent of the participants were taking prednisone, while 65 percent were on antimalarial therapy. Nearly half of the patients (49 percent) used concurrent immunosuppressive therapy.

Vitamin D deficiency (<20 ng/mL) was found in 40.6 percent of participants, while vitamin D insufficiency (20–29 ng/mL) was 49.4 percent. Mean serum 25(OH)D concentrations did not differ significantly in patients with neuropsychiatric (23.2 ng/mL), haematological (22.0 ng/mL) and nephritis lupus (21.7 ng/mL) manifestations.

About half of the participants (49.3 percent) had metabolic syndrome. The likelihood of having metabolic syndrome decreased with increasing quartiles of 25(OH)D concentrations (p-trend=0.03). Compared with the lowest 25(OH)D quartile, the highest quartile was associated with 60-percent reduced odds of having metabolic syndrome (odds ratio [OR], 0.4, 95 percent confidence interval, 0.2–0.9; p=0.04). Similarly, the odds of having elevated hypertriglyceridemia decreased according to increasing quartiles of 25(OH)D concentrations (p-trend=0.036).

However, this association between 25(OH)D concentrations and MetS and its individual components disappeared after controlling for body mass index and smoking.

Researchers underscored a need for large prospective studies to establish the roles of 25(OH)D in the incidence of metabolic syndrome in SLE patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
09 Jan 2020
Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.
Stephen Padilla, 3 days ago
Brodalumab has exhibited long-term efficacy and consistent safety profile for more than 2 years in the treatment of patients with psoriasis, results of the phase III AMAGINE-2 trial show.